中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
16期
31-34
,共4页
张莉%杨保仲%汪祖巾%王春燕%贾文霞
張莉%楊保仲%汪祖巾%王春燕%賈文霞
장리%양보중%왕조건%왕춘연%가문하
电休克治疗%骨骼肌松弛药%罗库溴铵%琥珀胆碱
電休剋治療%骨骼肌鬆弛藥%囉庫溴銨%琥珀膽堿
전휴극치료%골격기송이약%라고추안%호박담감
Electroshock therapy%Neuromuscular blocking agent%Rocuronium%Suxamethonium
目的:探讨两种剂量组罗库溴铵与琥珀胆碱运用于麻醉状态下无抽搐电休克治疗精神疾病患者肌松效果的影响。方法:选择确诊为精神疾病、有明确电休克治疗适应证、ASA分级I级、年龄18~50岁、1周接受3次电休克治疗且平均至少接受6次治疗的患者60例,按随机数字表法分为三组,分别以0.3 mg/kg(R1组)、0.45 mg/kg(R2组)罗库溴铵和1 mg/kg琥珀胆碱(S组)配伍丙泊酚(1 mg/kg)用作麻醉诱导,电抽搐治疗后R1、R2组给予新斯的明(0.1 mg/kg)加阿托品(0.05 mg/kg)拮抗罗库溴铵,比较三组患者治疗后自主呼吸恢复时间、睁眼时间、肢体运动时间以及电击前与电击时心率、血压及血氧饱和度的变化。结果:R2组自主呼吸恢复时间较其他两组长,差异均有统计学意义(P<0.05);三组睁眼时间、体动时间比较差异均无统计学意义(P>0.05);三组诱导后与电击时心率、血压及血氧饱和度差值比较差异均无统计学意义(P>0.05)。结论:0.45 mg/kg罗库溴铵可导致患者自主呼吸恢复时间延长,不推荐运用于无抽搐电休克治疗;0.3 mg/kg罗库溴铵复合使用肌松拮抗药可作为琥珀胆碱的替代药物运用于无抽搐电休克治疗。
目的:探討兩種劑量組囉庫溴銨與琥珀膽堿運用于痳醉狀態下無抽搐電休剋治療精神疾病患者肌鬆效果的影響。方法:選擇確診為精神疾病、有明確電休剋治療適應證、ASA分級I級、年齡18~50歲、1週接受3次電休剋治療且平均至少接受6次治療的患者60例,按隨機數字錶法分為三組,分彆以0.3 mg/kg(R1組)、0.45 mg/kg(R2組)囉庫溴銨和1 mg/kg琥珀膽堿(S組)配伍丙泊酚(1 mg/kg)用作痳醉誘導,電抽搐治療後R1、R2組給予新斯的明(0.1 mg/kg)加阿託品(0.05 mg/kg)拮抗囉庫溴銨,比較三組患者治療後自主呼吸恢複時間、睜眼時間、肢體運動時間以及電擊前與電擊時心率、血壓及血氧飽和度的變化。結果:R2組自主呼吸恢複時間較其他兩組長,差異均有統計學意義(P<0.05);三組睜眼時間、體動時間比較差異均無統計學意義(P>0.05);三組誘導後與電擊時心率、血壓及血氧飽和度差值比較差異均無統計學意義(P>0.05)。結論:0.45 mg/kg囉庫溴銨可導緻患者自主呼吸恢複時間延長,不推薦運用于無抽搐電休剋治療;0.3 mg/kg囉庫溴銨複閤使用肌鬆拮抗藥可作為琥珀膽堿的替代藥物運用于無抽搐電休剋治療。
목적:탐토량충제량조라고추안여호박담감운용우마취상태하무추휵전휴극치료정신질병환자기송효과적영향。방법:선택학진위정신질병、유명학전휴극치료괄응증、ASA분급I급、년령18~50세、1주접수3차전휴극치료차평균지소접수6차치료적환자60례,안수궤수자표법분위삼조,분별이0.3 mg/kg(R1조)、0.45 mg/kg(R2조)라고추안화1 mg/kg호박담감(S조)배오병박분(1 mg/kg)용작마취유도,전추휵치료후R1、R2조급여신사적명(0.1 mg/kg)가아탁품(0.05 mg/kg)길항라고추안,비교삼조환자치료후자주호흡회복시간、정안시간、지체운동시간이급전격전여전격시심솔、혈압급혈양포화도적변화。결과:R2조자주호흡회복시간교기타량조장,차이균유통계학의의(P<0.05);삼조정안시간、체동시간비교차이균무통계학의의(P>0.05);삼조유도후여전격시심솔、혈압급혈양포화도차치비교차이균무통계학의의(P>0.05)。결론:0.45 mg/kg라고추안가도치환자자주호흡회복시간연장,불추천운용우무추휵전휴극치료;0.3 mg/kg라고추안복합사용기송길항약가작위호박담감적체대약물운용우무추휵전휴극치료。
Objective:To discuss the influence of different doses of rocuronium and suxamethonium applied to modified electroshock therapy( ECT) under anesthesia to treat mental patient with neuromuscular blocking. Method:Patients diagnosed as mental illness should be chosen and must be characterized by explicit electroshock therapy indications. The classification of ASA was at I level and their ages should be between 18 and 50.All patients received ECT for three times a week and must received ECT for at average about six times at least. 60 patients were divided into three groups according to random number table method,the control group was 1 mg/kg suxamethonium group( the group S), the treatment groups were 0.3 mg/kg( the group R1) rocuronium group and 0.45 mg/kg( the group R2) rocuronium group, all these groups should be respectively combined with propofol(1 mg/kg) as anesthesia induction. After ECT, neostigmine (0.1 mg/kg)and atropine(0.05 mg/kg) antagonism rocuronium were added to the two group doses of rocuronium. Consequently, the comparison shall be made among three patients on the recovery time of automatic respiration, the time to open eyes, the time of body movement as well as the heart rate and the change of blood pressure and oxygen saturation before electroshock and during electroshock.Result: The patients’ automatic respiration recovery time of the R2 group were significantly longer than the other groups, the differences were statistical significance( P<0.05).There were no statistical significance in the time of opening eyes and body movement among the three groups(P>0.05);no matter before electroshock or during electroshock, there were no statistical significance in patients’ HR, the change of BP and SpO2 among three groups(P>0.05). Conclusion:0.45 mg/kg rocuronium can result in extending the recovery time of patients’ automatic respiration.,so it’s not supported to be applied to modified electroshock therapy; 0.3 mg/kg rocuronium used with neuromuscular blocking antagonist can be the replacement for suxamethonium being applied to modified electroshock therapy.